Transforming Treatment in
HIV and Hep C
Over the last three decades we’ve created revolutionary therapies for people living with HIV and hepatitis C, and developed a reputation for innovation that’s second to none.
We introduced 4 medicines in less than 4 years that offer a cure for the majority of people living with chronic hepatitis C.
We pioneered the first-single tablet HIV regimen and developed the first medicine to prevent HIV infection.
Ranked number 1 in the 2019 Pharmaceutical Innovation Index.
Our Impact, by the Numbers
Patients in over 130 countries reached with our treatment programs, in collaboration with international and local partners on the ground.
27 marketed drugs
27 marketed drugs and an active R&D program.
More than 4 million people worldwide have been treated with Gilead-based HCV and HBV regimens.
An estimated 12.6 million people who live with HIV in resource-challenged countries receive a Gilead-based treatment every day.
Pioneering Research to Create Unique Targeted Therapies
Driven by a need to make great things happen, we’ve used state-of-the-art human biotechnology to discover and develop unique therapies.
A bold and agile approach to drug discovery, powered by the philosophy: If it doesn’t happen, make it happen.
Cutting-edge biotech that uses human cells from patients to discover novel targets for medicines to beat severe diseases.
A unique discovery platform that uses a vast adenoviral library to identify specific protein targets at the root cause of chronic disease, develop small molecule therapies aimed at those novel targets, and bring molecules rapidly to clinical trials.